BioSpace News Archive

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations.

The U.S. Pharmacopeia announced the opening of the USP Advanced Manufacturing Technology Lab in Richmond, Virginia as part of its launch of a suite of R&D analytical solutions.

Personalis, Inc. today announced its NeXT Personal ® cancer assay earned the top spot on The Scientist’s Top 10 Innovations of 2022 list.

CARsgen Therapeutics Holdings Limited announces that at the 2022 American Society of Hematology (the “ASH”) Annual Meeting, the Company presented a poster with the results of the phase II LUMMICAR STUDY 1 clinical trial of zevorcabtagene autoleucel.

Brand Institute, the global leader in pharmaceutical and healthcare-related name development, considers mRNA vaccines for the treatment of cancer to be an exciting area of research that, though still in its infancy, will continue to grow.

PureTech Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology (ASH) Annual Meeting.

AVITA Medical, Inc. announced today the submission of a Premarket Approval (PMA) supplement application to the U.S. Food and Drug Administration (FDA) for the company’s RECELL ® System.

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the company presents new scientific data including one clinical abstract and three preclinical research posters at the Annual American Society of Hematology Meeting, ASH, in New Orleans, Louisiana, USA, on December 10-13.

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) today announced the presentation of clinical data from the Phase 1a dose escalation part of the ASPEN-05 trial evaluating evorpacept in combination with azacitidine and venetoclax for the treatment of patients with relapsed or refractory (“r/r”) or newly diagnosed (“ND”) acute myeloid leukemia (“AML”).

Keros Therapeutics, Inc. announced that it presented additional data from its ongoing Phase 2 clinical trial of KER-050 in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes, as well as initial data from its ongoing Phase 2 clinical trial of KER-050 in patients with myelofibrosis and from its ongoing Phase 2 clinical trial of KER-047 in patients with iron-refractory iron deficiency anemia, at the 64th ASH Annual Meeting and Exposition.